Latest Conference Articles

The Patient Impact of CDI, Preventing Reoccurrence

The Patient Impact of CDI, Preventing Reoccurrence

June 1st 2022, 12:00pm

MAD-ID

A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.

The Next Big Thing in Stewardship?

The Next Big Thing in Stewardship?

May 29th 2022, 3:58pm

MAD-ID

A clinician is advocating for incorporating diagnostic stewardship practices within antimicrobial stewardship programs, which could someday lead to best practice guidelines on a larger scale.

Rapid Diagnostic Testing’s Impact on Timing to Optimal Therapy

Rapid Diagnostic Testing’s Impact on Timing to Optimal Therapy

May 27th 2022, 1:59pm

MAD-ID

Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.

Measuring the Effectiveness of a Novel Antibiotic for Patients with Nontuberculous Mycobacterial Infections

Measuring the Effectiveness of a Novel Antibiotic for Patients with Nontuberculous Mycobacterial Infections

May 27th 2022, 12:16pm

MAD-ID

A multicenter study looked at treating these infections with omadacycline.

Monoclonal Antibody ADG20 Neutralizes COVID-19 Variants

Monoclonal Antibody ADG20 Neutralizes COVID-19 Variants

May 26th 2022, 6:09pm

MAD-ID | Making a Difference in Infectious Diseases

The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.

Monitoring Vancomycin Area Under the Curve Dosing

Monitoring Vancomycin Area Under the Curve Dosing

May 26th 2022, 11:52am

MAD-ID

A medical center wanted to review prescribing and documentation practices for their pharmacists.

Investigating RBX2660 for Recurrent C Difficile Infection

Investigating RBX2660 for Recurrent C Difficile Infection

May 24th 2022, 6:00pm

MAD-ID | Making a Difference in Infectious Diseases

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Examining Oral Vancomycin as a First-Line CDI Therapy

Examining Oral Vancomycin as a First-Line CDI Therapy

May 24th 2022, 5:22pm

MAD-ID

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

Assessing Vancomycin and Metronidazole Susceptibility for CDI

Assessing Vancomycin and Metronidazole Susceptibility for CDI

May 23rd 2022, 6:15pm

MAD-ID

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.

The Role of a Stewardship Pharmacist in Treating UTIs in the Outpatient Setting

The Role of a Stewardship Pharmacist in Treating UTIs in the Outpatient Setting

May 22nd 2022, 5:00pm

MAD-ID

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.